Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIML NK Cell Adoptive Therapy for Relapsed AML After Allo-HCT
NCT03068819Phase 2Completed
- Sponsor
- Washington University School of Medicine
- Start
- Oct 2017
- Primary completion
- Jun 2025
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Lymphokine-Activated Killer Cells
- Countries
- 1
01
Overview
A Phase 2 trial of cytokine-induced memory-like natural killer cells in acute myeloid leukemia (AML), sponsored by Washington University School of Medicine. Started Oct 2017; status: completed.
02
Drugs
cytokine-induced memory-like natural killer cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03068819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03068819.